Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chao Hu
Institution:
Chengdu University of Traditional Chinese Medicine
Observed institution:
Chengdu University of Traditional Chinese Medicine
ORCID:
0000-0002-1260-7788
Observed ORCID:
0000-0002-1260-7788
OpenAlex ID:
A5024294172
Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2022
·
Peng Peng
, Xiaoyan Qiang
, et al.
·
Molecular Cancer Therapeutics
·
34
High-throughput profiling of chemical-induced gene expression across 93,644 perturbations
2025
·
Lei Xiang
, Yumei Wang
, et al.
·
Nature Methods
·
26
The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment
2024
·
Yan Luo
, Guochen Zhang
, et al.
·
Molecules
·
18
Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer
2023
·
Yumei Wang
, Haiyan Wang
, et al.
·
Cancer Biology and Medicine
·
8
PDF
Identification of chemical inhibitors targeting long noncoding RNA through gene signature-based high throughput screening
2024
·
Jun An
, Huili Wang
, et al.
·
International Journal of Biological Macromolecules
·
3
Figure FS2 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
·
1
Figure FS7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2025
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS5 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2025
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS3 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS2 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Supplementary Tables S1-7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS6 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS4 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS8 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS9 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS5 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS9 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Supplementary Tables S1-7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS5 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS6 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Figure FS3 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
2023
·
Peng Peng
, Xiaoyan Qiang
, et al.
Show more works
View as search
Works count:
34
Citation count:
90
H-index:
4
I10-index:
3
Year
Topic
Type